Results 111 to 120 of about 5,598,449 (384)

Survival outcomes in men with a positive family history of prostate cancer: a registry based study

BMC Cancer, 2020
Background To investigate the correlation between family history of prostate cancer (PCa) and survival (overall and cancer specific) in patients undergoing treatment for PCa.
Mann Ang, Martin Borg, Michael E. O’Callaghan, for the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC)   +3 more
doaj   +1 more source

Cancer statistics, 2020

Ca, 2020
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population‐based cancer occurrence.
R. Siegel, K. D. Miller, A. Jemal
semanticscholar   +1 more source

The PTTG1/VASP axis promotes oral squamous cell carcinoma metastasis by modulating focal adhesion and actin filaments

Molecular Oncology, EarlyView.
VASP was found to be overexpressed in metastatic oral squamous cell carcinoma (OSCC) tissues. Notably, PTTG1‐ and VASP‐deficient OSCC cells demonstrated suppressed metastatic properties by disrupting the interaction between the cytoskeleton and focal adhesion (FAs) in the filopodia region.
Suyeon Park, Sang Shin Lee, Shihyun Kim, Yeonjun Lee, Gyeonwon Park, Jung Oh Kim, Jongho Choi   +6 more
wiley   +1 more source

Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology

Molecular Oncology, EarlyView.
The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang, Anna Schritz, Nikolai Goncharenko, Guy Berchem   +3 more
wiley   +1 more source

Impact of COVID-19 on the time to counseling and treatment of prostate cancer

The Aging Male
Purpose This study investigates how the COVID-19 pandemic (CP) impacted the timeline between initial diagnosis (ID) of prostate carcinoma and subsequent therapy consultation (TC) or radical prostatectomy (RP) due to the implementation of a “minimal ...
Dejan K. Filipas, Randi M. Pose, Phillip Marks, Pierre Tennstedt, Burkhard Beyer, Derya Tilki, Hendrik Isbarn, Tobias Maurer, Tim A. Ludwig, Hans Heinzer, Thomas Steuber   +10 more
doaj   +1 more source

Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

BMC Cancer, 2019
Background The differences in progression-free survival (PFS) and cancer-specific survival (CSS) of metastatic renal cell carcinoma (mRCC) patients according to treatment, type of metastasis, and Heng criteria risk are unclear. In this study, we compared
Sung Han Kim, Dong-eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung   +7 more
doaj   +1 more source

What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review

BMJ Open, 2020
Objective To investigate the risk of prostate cancer-specific mortality (PCSM) following initial negative systematic transrectal ultrasound-guided (TRUS) prostate biopsies.Design Systematic review.Data sources PubMed and Embase were searched using a ...
Klaus Brasso, Martin Andreas Roder, Sandra Miriam Kawa, Signe Benzon Larsen, John Thomas Helgstrand, Peter Iversen   +5 more
doaj   +1 more source

Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: A nested case-control study [PDF]

, 2014
Vitamin D pathway single nucleotide polymorphisms (SNPs) are potentially useful proxies for investigating whether circulating vitamin D metabolites [total 25-hydroxyvitamin-D, 25(OH)D; 1,25-dihydroxyvitamin, 1,25(OH)2D] are causally related to prostate ...
Bonilla, Carolina, Donovan, Jenny L., Evans, David M., Fraser, William D., Gilbert, Rebecca, Hamdy, Freddie C., Kemp, John P., Lane, J. Athene, Lathrop, Mark, Lewis, Sarah, Martin, Richard M., Metcalfe, Chris, Neal, David E., Smith, George Davey   +13 more
core   +3 more sources

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

Molecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy, Heather Fairfield, Victoria E. DeMambro, Samaa Fadel, Carlos A. Gartner, Michelle Karam, Christian Potts, Princess Rodriguez, Ya‐Wei Qiang, Habib Hamidi, Xiangnan Guan, Calvin P. H. Vary, Michaela R. Reagan   +12 more
wiley   +1 more source

Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer. [PDF]

, 2016
Genomic loss of chromosome (chr) 8p21 region, containing prostate-specific NKX3.1 gene, is a frequent alteration of the prostate cancer (PCa) oncogenome.
Bucay, Nathan, Dahiya, Rajvir, Deng, Guoren, Greene, Kirsten, Majid, Shahana, Saini, Sharanjot, Sekhon, Kirandeep, Shahryari, Varahram, Tabatabai, Z Laura, Tanaka, Yuichiro, Yamamura, Soichiro   +10 more
core   +1 more source